MedPath
Found 18 clinical trials|View Analysis
Sort by:

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Locally Advanced Gastric Adenocarcinoma
Locally Advanced Gastroesophageal Junction Adenocarcinoma
Locally Advanced Skin Squamous Cell Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Clinical Stage IVB Gastric Cancer AJCC v8
Locally Advanced Renal Cell Carcinoma
Interventions
Drug: Cyclophosphamide
Biological: Neoantigen Peptide Vaccine
Biological: Pembrolizumab
Biological: Sargramostim
First Posted Date
2022-03-08
Last Posted Date
2024-06-12
Lead Sponsor
Mayo Clinic
Target Recruit Count
36
Registration Number
NCT05269381
Locations
🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Phase 2
Recruiting
Conditions
Stage IVB Hepatocellular Carcinoma AJCC v8
Metastatic Hepatocellular Carcinoma
Stage IV Hepatocellular Carcinoma AJCC v8
Stage IVA Hepatocellular Carcinoma AJCC v8
Unresectable Hepatocellular Carcinoma
BCLC Stage B Hepatocellular Carcinoma
Locally Advanced Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma AJCC v8
Stage IIIA Hepatocellular Carcinoma AJCC v8
BCLC Stage C Hepatocellular Carcinoma
Interventions
Biological: Ipilimumab
Biological: Nivolumab
First Posted Date
2022-01-20
Last Posted Date
2023-10-16
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
40
Registration Number
NCT05199285
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

🇺🇸

University of Alabama- Birmingham, Birmingham, Alabama, United States

🇺🇸

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

and more 3 locations

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Phase 2
Recruiting
Conditions
Locally Advanced Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma AJCC v8
Stage IIIA Hepatocellular Carcinoma AJCC v8
Stage IIIB Hepatocellular Carcinoma AJCC v8
Stage IVB Hepatocellular Carcinoma AJCC v8
Metastatic Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Stage IVA Hepatocellular Carcinoma AJCC v8
Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Drug: Cabozantinib
Biological: Atezolizumab
Drug: Lenvatinib
First Posted Date
2021-12-23
Last Posted Date
2024-04-04
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
122
Registration Number
NCT05168163
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Rapid City Regional Hospital, Rapid City, South Dakota, United States

🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 13 locations

Y-90 Versus SBRT for Inoperable HCC

Phase 2
Withdrawn
Conditions
Stage I Hepatocellular Carcinoma AJCC v8
Stage IA Hepatocellular Carcinoma AJCC v8
Stage IB Hepatocellular Carcinoma AJCC v8
Hepatocellular Carcinoma
Stage II Hepatocellular Carcinoma AJCC v8
Stage III Hepatocellular Carcinoma AJCC v8
Stage IVA Hepatocellular Carcinoma AJCC v8
Stage IIIB Hepatocellular Carcinoma AJCC v8
Stage IIIA Hepatocellular Carcinoma AJCC v8
Interventions
Other: Quality of Life
Other: Questionnaire Administration
Radiation: Stereotactic Body Radiation Therapy
Procedure: Yttrium-90 Microsphere Radioembolization
First Posted Date
2021-12-15
Last Posted Date
2023-03-23
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT05157451

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Phase 2
Recruiting
Conditions
Recurrent Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma AJCC V8
Stage IIIA Hepatocellular Carcinoma AJCC V8
Stage IIIB Hepatocellular Carcinoma AJCC V8
Stage IV Hepatocellular Carcinoma AJCC V8
Stage IVA Hepatocellular Carcinoma AJCC V8
Stage IVB Hepatocellular Carcinoma AJCC V8
Unresectable Hepatocellular Carcinoma
Interventions
Other: Laboratory Biomarker Analysis
Drug: Lenvatinib
First Posted Date
2021-11-02
Last Posted Date
2024-12-27
Lead Sponsor
Emory University
Target Recruit Count
19
Registration Number
NCT05103904
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Mayo Clinic Arizona, Scottsdale, Arizona, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Phase 1
Recruiting
Conditions
Advanced Breast Carcinoma
Advanced Endometrial Carcinoma
Advanced Fallopian Tube Carcinoma
Advanced Hepatocellular Carcinoma
Advanced Malignant Abdominal Neoplasm
Advanced Malignant Female Reproductive System Neoplasm
Advanced Malignant Thoracic Neoplasm
Advanced Ovarian Carcinoma
Advanced Primary Peritoneal Carcinoma
Advanced Renal Cell Carcinoma
Interventions
First Posted Date
2021-10-25
Last Posted Date
2024-12-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
43
Registration Number
NCT05092373
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events

Not Applicable
Recruiting
Conditions
Clinical Stage IV Gastric Cancer AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage IVB Gastric Cancer AJCC v8
Metastatic Rectal Carcinoma
Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8
Metastatic Gastric Carcinoma
Metastatic Malignant Digestive System Neoplasm
Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8
Interventions
Other: Best Practice
Other: Questionnaire Administration
Procedure: Patient Monitoring
First Posted Date
2021-09-09
Last Posted Date
2024-07-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
750
Registration Number
NCT05038254
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Phase 1
Recruiting
Conditions
Locally Advanced Hepatocellular Carcinoma
Stage IIIB Hepatocellular Carcinoma AJCC v8
Stage IIIA Hepatocellular Carcinoma AJCC v8
Stage IV Hepatocellular Carcinoma AJCC v8
Unresectable Hepatocellular Carcinoma
BCLC Stage B Hepatocellular Carcinoma
Stage IVA Hepatocellular Carcinoma AJCC v8
BCLC Stage C Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma AJCC v8
Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions
Biological: Durvalumab
Biological: Tremelimumab
First Posted Date
2020-10-28
Last Posted Date
2024-01-30
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
32
Registration Number
NCT04605731
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition

Phase 2
Recruiting
Conditions
Stage IVA Hepatocellular Carcinoma AJCC v8
Stage IIIA Hepatocellular Carcinoma AJCC v8
Advanced Hepatocellular Carcinoma
Stage IIIB Hepatocellular Carcinoma AJCC v8
Stage III Hepatocellular Carcinoma AJCC v8
Stage IV Hepatocellular Carcinoma AJCC v8
Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions
Biological: Durvalumab
Radiation: Hypofractionated Radiation Therapy
Biological: Tremelimumab
First Posted Date
2020-06-12
Last Posted Date
2023-08-02
Lead Sponsor
Mary Feng, MD
Target Recruit Count
21
Registration Number
NCT04430452
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Phase 1
Suspended
Conditions
Stage III Hepatocellular Carcinoma AJCC v8
Stage IIIA Hepatocellular Carcinoma AJCC v8
Stage IVB Hepatocellular Carcinoma AJCC v8
Stage IIIB Hepatocellular Carcinoma AJCC v8
Stage IV Hepatocellular Carcinoma AJCC v8
Stage IVA Hepatocellular Carcinoma AJCC v8
Unresectable Fibrolamellar Carcinoma
Interventions
Drug: Fluorouracil
Biological: Nivolumab
Biological: Recombinant Interferon Alpha 2b-like Protein
First Posted Date
2020-05-08
Last Posted Date
2024-11-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
15
Registration Number
NCT04380545
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath